PedAM

Pediatric Disease Annotations & Medicines

Disease	hepatorenal syndrome
Phenotype	C0023890\|cirrhosis
Sentences	22
PubMedID- 24151614	[20] showed that survival of pts with type 1 hepatorenal syndrome associated with cirrhosis varied with liver disease etiology.
PubMedID- 24508549	Type-1 hepatorenal syndrome in patients with cirrhosis and infection vs.
PubMedID- 21285885	Prevention of hepatorenal syndrome in patients with cirrhosis and ascites: a pilot randomized control trial between pentoxifylline and placebo.
PubMedID- 19710033	Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment.
PubMedID- 25298585	hepatorenal syndrome (hrs) occurs in patients with cirrhosis, ascites and hepatic failure.
PubMedID- 25903705	Magnetic resonance elastography in the detection of hepatorenal syndrome in patients with cirrhosis and ascites.
PubMedID- 23682235	The coming years may very well see increased use of pentoxifylline as a prophylactic agent to prevent hepatorenal syndrome in patients with concurrent cirrhosis and ascites.
PubMedID- 22971333	Non-inclusion criteria were pregnancy, age of less than 18 years, known renal artery stenosis, known end-stage renal disease or chronic kidney disease defined by a glomerular filtration rate (gfr) of less than 30 ml/minute per 1.73 m2, angiotensin-converting enzyme inhibitor and non-steroidal anti-inflammatory treatment, cirrhosis with hepatorenal syndrome, and a major cardiogenic component in septic shock defined as a need for epinephrine or dobutamine or both.
PubMedID- 25983746	Treatment of hepatorenal syndrome (hrs) in patients with liver cirrhosis is still challenging and characterized by a very high mortality.
PubMedID- 19837678	Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites.
PubMedID- 22637695	Background: hepatorenal syndrome in cirrhosis with ascites is a well-defined entity with significant morbidity and mortality.
PubMedID- 21484118	Aim: evaluation of the clinical significance of cystatin c as a predictor of hepatorenal syndrome (hrs) in patients with liver cirrhosis, ascites, and normal serum cr level.
PubMedID- 20581246	Refractory ascites is a frequent complication of advanced cirrhosis and is associated with hepatorenal syndrome and hepatic hydrothorax.
PubMedID- 26187817	Our findings may be clinically relevant since the inability to increase cardiac output under stress conditions (such as infection or haemorrhage) may play a role in the development of hepatorenal syndrome, influencing mortality in patients with cirrhosis [11, 12].
PubMedID- 21858100	This overproduction of proinflammatory cytokines leads to various complications, such as spontaneous bacterial peritonitis (sbp) and hepatorenal syndrome (hrs) in patients with advanced cirrhosis [5], [6].
PubMedID- 23788898	Secondary to hbv or hcv) accompanied by intensive regenerative processes,patients with adenocarcinoma metastases into the liver,liver cirrhosis complicated by hepatorenal syndrome,non-alcoholic fatty liver disease,renal failure.
PubMedID- 22811919	cirrhosis patients with hepatorenal syndrome often need dialysis.
PubMedID- 19952764	Objectives: renal failure is common in cirrhosis frequently due to hepatorenal syndrome (hrs).
PubMedID- 22057374	Cystatin c is a good predictor of hepatorenal syndrome and survival in patients with cirrhosis who have normal serum creatinine levels.
PubMedID- 22055590	Serum cystatin c in advanced liver cirrhosis and different stages of the hepatorenal syndrome.
PubMedID- 22094211	hepatorenal syndrome occurs in patients with advanced liver cirrhosis and is associated with functional renal impairment and poor prognosis.
PubMedID- 24631577	Nonselective beta blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis.

Page: 1